Antitumor CAS 183319-69-9 Erlotinib HCl Raw Erlotinib Hydrochloride Powder Pharmaceutical Erlotinib Hydrochloride

• Powder: Yes
• Customized: Customized
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Adult
• State: Powder
• Purity: >99%
• Model NO.: D-sung Erlotinib Hydrochloride
• Product Name: Erlotinib Hydrochloride
• Name: Erlotinib HCl
• Appearance: White Powder
• Color: White
• Grade: Pharmaceutical Grade
• Assay: HPLC 99%
• Application: Pharmaceutical;Antitumor ;Antineoplastic
• Specific: COA
• Test Method: HPLC
• Shelf Life: 2 Years
• CAS No.: 183319-69-9
• Mf: C22h24cln3o4
• MW: 429.901
• Melting Point: 223-225°c
• Boiling Point: 553.6 °c at 760 Mmhg
• Transport Package: Negotiable
• Specification: 99%
• Trademark: D-sung
• Origin: Shaanxi Xi′an
• Production Capacity: 500kg/Month

Product Description

CAS 183319-69-9 Antitumor Erlotinib HCL Raw Erlotinib Hydrochloride Powder Pharmaceutical Erlotinib Hydrochloride

Product Description

Product Details

Product name	Erlotinib Hydrochloride
Appearance	White powder
Cas number	183319-69-9
MF	C22H24ClN3O4
MW	429.901

Erlotinib hydrochlorate is a small molecule tyrosine kinase inhibitor which acts reversibly on epidermal growth factor receptors, a hydrochloride of erlotinib, a molecular-targeted drug. The US Food and Drug Administration (FDA) has approved erlotinib (Tarceva) combined with gemcitabine as a first-line treatment for locally advanced and metastatic pancreatic cancer.

It is mainly used as a second- or third-line treatment for locally advanced or metstatic non-small cell lung cancer (NSCLC) and as a treatment for pancreatic cancer. It is used as a tyrosine inhibitor for NSCLC treatment.

Application&Function

1. Erlotinib hydrochloride is a kind of small molecule epidermal growth factor receptor tyrosine kinase reversible inhibitor. It is mainly used for the second-line or third-line treatment of locally advanced or metastatic non-small cell lung cancer and for the treatment of pancreatic cancer.

2. HER-1/EGFR tyrosine kinase inhibitors.

Specification